Cytarabine, an antimetabolic agent currently used for the treatment of AML, was previously shown to induce phosphorylation of eIF4E on serine 209, which could constitute a potential anti-cancer resistance mechanism activated during administration of this therapy [31]. Here, EIF4E is linked to acute myeloid leukemia.